extract: 2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics
Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA>
This commit is contained in:
Teleo Agents
parent
2d6a1cc7a2
commit
37e541a987
6 changed files with 65 additions and 1 deletions
|
|
@ -95,6 +95,12 @@ WHO's conditional recommendation structure and behavioral therapy requirement su
|
|||
|
||||
If GLP-1 + exercise produces durable weight maintenance (3.5 kg regain vs 8.7 kg for medication alone), then the chronic use assumption may be wrong. Patients who establish exercise habits during a 1-2 year medication window may not need indefinite treatment, fundamentally changing the cost trajectory. The inflationary projection assumes continuous medication; the combination data suggests a time-limited intervention model may be viable.
|
||||
|
||||
|
||||
### Additional Evidence (challenge)
|
||||
*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-18*
|
||||
|
||||
Value in Health modeling study shows Medicare saves $715M over 10 years with comprehensive semaglutide access across all indications, challenging the universal inflationary framing. The distinction is payment structure: risk-bearing integrated payers can be net positive while fragmented systems remain inflationary. T2D savings ($892M) exceed obesity costs ($205M) when multi-indication benefits compound.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -54,6 +54,12 @@ FLOW trial demonstrated 29% reduction in cardiovascular death (HR 0.71, 95% CI 0
|
|||
|
||||
Quantified lifetime savings per subject: $14,431 from avoided T2D, $2,074 from avoided CKD, $1,512 from avoided CV events. Diabetes prevention is the dominant economic driver, not cardiovascular protection, suggesting targeting should prioritize metabolic risk over CV risk.
|
||||
|
||||
|
||||
### Additional Evidence (confirm)
|
||||
*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-18*
|
||||
|
||||
Medicare modeling quantifies the compound value: 38,950 CV events avoided, 6,180 deaths prevented over 10 years. Per 100,000 subjects: 2,791 MIs, 3,000 revascularizations, 487 strokes, 115 CV deaths avoided. Savings per subject: $14,431 from avoided T2D, $2,074 from avoided CKD, $1,512 from avoided CV events. The multi-organ protection creates sufficient offset to produce net savings when a single payer captures all benefits.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -40,6 +40,12 @@ FLOW trial (N=3,533, median 3.4 years follow-up) showed 24% reduction in major k
|
|||
|
||||
SELECT trial economic model shows $2,074 per-subject lifetime savings from avoided CKD, supporting the claim that kidney protection generates substantial cost savings. However, diabetes prevention ($14,431) generates even larger savings.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-18*
|
||||
|
||||
In the Medicare comprehensive model, CKD-related savings contribute $2,074 per subject treated, which is smaller than T2D savings ($14,431/subject) but still material. The 10-year modeling window may underestimate dialysis delay value since ESRD costs accumulate over longer periods. MASH savings were only $28M system-wide, suggesting treatment costs don't accumulate enough in the 10-year window to produce large offsets despite clinical efficacy.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -37,6 +37,12 @@ The composition of spending shifts dramatically: less on chronic disease managem
|
|||
|
||||
(extend) The Medicare trust fund fiscal pressure adds a constraint layer to the cost curve dynamics. While new capabilities create upward cost pressure through expanded treatment populations, the trust fund exhaustion timeline (now 2040, accelerated from 2055 by tax policy changes) creates a hard fiscal boundary. The convergence of demographic pressure (working-age to 65+ ratio declining to 2.2:1 by 2055), MA overpayments ($1.2T/decade), and reduced tax revenues means automatic 8-10% benefit cuts starting 2040 unless structural reforms occur. This fiscal ceiling will force coverage and payment decisions in the 2030s independent of technology trajectories, potentially constraining the cost curve expansion that new capabilities would otherwise enable.
|
||||
|
||||
|
||||
### Additional Evidence (extend)
|
||||
*Source: [[2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics]] | Added: 2026-03-18*
|
||||
|
||||
The Medicare semaglutide analysis provides a boundary condition: when payment is integrated and multi-indication benefits compound, prevention CAN bend the cost curve down for specific payers. However, this requires: (1) single entity bearing costs and capturing savings, (2) multi-indication efficacy across high-cost conditions, (3) sufficient persistence to realize benefits. The system-level curve may still bend up while risk-bearing integrated payers see net savings—a payment structure divergence.
|
||||
|
||||
---
|
||||
|
||||
Relevant Notes:
|
||||
|
|
|
|||
|
|
@ -0,0 +1,24 @@
|
|||
{
|
||||
"rejected_claims": [
|
||||
{
|
||||
"filename": "comprehensive-semaglutide-access-saves-medicare-715m-over-10-years-because-multi-indication-benefits-offset-drug-costs-when-single-payer-bears-both.md",
|
||||
"issues": [
|
||||
"missing_attribution_extractor"
|
||||
]
|
||||
}
|
||||
],
|
||||
"validation_stats": {
|
||||
"total": 1,
|
||||
"kept": 0,
|
||||
"fixed": 1,
|
||||
"rejected": 1,
|
||||
"fixes_applied": [
|
||||
"comprehensive-semaglutide-access-saves-medicare-715m-over-10-years-because-multi-indication-benefits-offset-drug-costs-when-single-payer-bears-both.md:set_created:2026-03-18"
|
||||
],
|
||||
"rejections": [
|
||||
"comprehensive-semaglutide-access-saves-medicare-715m-over-10-years-because-multi-indication-benefits-offset-drug-costs-when-single-payer-bears-both.md:missing_attribution_extractor"
|
||||
]
|
||||
},
|
||||
"model": "anthropic/claude-sonnet-4.5",
|
||||
"date": "2026-03-18"
|
||||
}
|
||||
|
|
@ -7,9 +7,13 @@ date: 2025-06-01
|
|||
domain: health
|
||||
secondary_domains: [internet-finance]
|
||||
format: paper
|
||||
status: unprocessed
|
||||
status: enrichment
|
||||
priority: high
|
||||
tags: [glp-1, semaglutide, medicare, cost-effectiveness, cardiovascular, CKD, MASH]
|
||||
processed_by: vida
|
||||
processed_date: 2026-03-18
|
||||
enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints.md", "semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings.md", "the healthcare cost curve bends up through 2035 because new curative and screening capabilities create more treatable conditions faster than prices decline.md"]
|
||||
extraction_model: "anthropic/claude-sonnet-4.5"
|
||||
---
|
||||
|
||||
## Content
|
||||
|
|
@ -39,3 +43,15 @@ Key findings:
|
|||
PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
|
||||
WHY ARCHIVED: This study provides the strongest evidence that the "inflationary through 2035" framing needs scope qualification — system-level vs. payer-level economics diverge when downstream savings accrue to the same entity
|
||||
EXTRACTION HINT: Focus on the distinction between system-level cost impact (inflationary) and risk-bearing payer impact (potentially cost-saving). This is the core VBC interaction.
|
||||
|
||||
|
||||
## Key Facts
|
||||
- Medicare semaglutide modeling shows net savings of $715M over 10 years (range: $412M to $1.04B)
|
||||
- T2D-related impact: savings of ~$892 million over 10 years
|
||||
- Obesity-related impact: added costs of ~$205 million over 10 years
|
||||
- MASH-related impact: savings of ~$28 million over 10 years
|
||||
- 38,950 cardiovascular events avoided over 10 years with comprehensive semaglutide access
|
||||
- 6,180 deaths avoided (CV events + CKD/MASH progression)
|
||||
- Per 100,000 subjects treated: 2,791 non-fatal MIs avoided, 3,000 coronary revascularizations avoided, 487 non-fatal strokes avoided, 115 CV deaths avoided
|
||||
- Average per-subject lifetime treatment costs: $47,353
|
||||
- Savings from avoided T2D: $14,431/subject; avoided CKD: $2,074/subject; avoided CV events: $1,512/subject
|
||||
|
|
|
|||
Loading…
Reference in a new issue